IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v547y2017i7662d10.1038_nature23003.html
   My bibliography  Save this article

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Author

Listed:
  • Ugur Sahin

    (Biopharmaceutical New Technologies (BioNTech) Corporation
    TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
    University Medical Center of the Johannes Gutenberg University)

  • Evelyna Derhovanessian

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Matthias Miller

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Björn-Philipp Kloke

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Petra Simon

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Martin Löwer

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Valesca Bukur

    (Biopharmaceutical New Technologies (BioNTech) Corporation
    TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Arbel D. Tadmor

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Ulrich Luxemburger

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Barbara Schrörs

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Tana Omokoko

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Mathias Vormehr

    (Biopharmaceutical New Technologies (BioNTech) Corporation
    University Medical Center of the Johannes Gutenberg University)

  • Christian Albrecht

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Anna Paruzynski

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Andreas N. Kuhn

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Janina Buck

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Sandra Heesch

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Katharina H. Schreeb

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Felicitas Müller

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Inga Ortseifer

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Isabel Vogler

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Eva Godehardt

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Sebastian Attig

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
    University Medical Center of the Johannes Gutenberg University)

  • Richard Rae

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Andrea Breitkreuz

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Claudia Tolliver

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Martin Suchan

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Goran Martic

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Alexander Hohberger

    (University Medical Center of the Johannes Gutenberg University)

  • Patrick Sorn

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Jan Diekmann

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Janko Ciesla

    (EUFETS GmbH)

  • Olga Waksmann

    (EUFETS GmbH)

  • Alexandra-Kemmer Brück

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Meike Witt

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Martina Zillgen

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Andree Rothermel

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Barbara Kasemann

    (TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • David Langer

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Stefanie Bolte

    (Biopharmaceutical New Technologies (BioNTech) Corporation)

  • Mustafa Diken

    (Biopharmaceutical New Technologies (BioNTech) Corporation
    TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Sebastian Kreiter

    (Biopharmaceutical New Technologies (BioNTech) Corporation
    TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH)

  • Romina Nemecek

    (Medical University of Vienna)

  • Christoffer Gebhardt

    (German Cancer Research Center (DKFZ)
    University Medical Center Mannheim, Heidelberg University)

  • Stephan Grabbe

    (University Medical Center of the Johannes Gutenberg University)

  • Christoph Höller

    (Medical University of Vienna)

  • Jochen Utikal

    (German Cancer Research Center (DKFZ)
    University Medical Center Mannheim, Heidelberg University)

  • Christoph Huber

    (Biopharmaceutical New Technologies (BioNTech) Corporation
    TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
    University Medical Center of the Johannes Gutenberg University)

  • Carmen Loquai

    (University Medical Center of the Johannes Gutenberg University)

  • Özlem Türeci

    (CI3 - Cluster for Individualized Immunointervention e.V)

Abstract

The authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma.

Suggested Citation

  • Ugur Sahin & Evelyna Derhovanessian & Matthias Miller & Björn-Philipp Kloke & Petra Simon & Martin Löwer & Valesca Bukur & Arbel D. Tadmor & Ulrich Luxemburger & Barbara Schrörs & Tana Omokoko & Mathi, 2017. "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer," Nature, Nature, vol. 547(7662), pages 222-226, July.
    • Handle: RePEc:nat:nature:v:547:y:2017:i:7662:d:10.1038_nature23003
    DOI: 10.1038/nature23003
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature23003
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature23003?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Celina Tretter & Niklas Andrade Krätzig & Matteo Pecoraro & Sebastian Lange & Philipp Seifert & Clara Frankenberg & Johannes Untch & Gabriela Zuleger & Mathias Wilhelm & Daniel P. Zolg & Florian S. Dr, 2023. "Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    2. Naomi Hoenisch Gravel & Annika Nelde & Jens Bauer & Lena Mühlenbruch & Sarah M. Schroeder & Marian C. Neidert & Jonas Scheid & Steffen Lemke & Marissa L. Dubbelaar & Marcel Wacker & Anna Dengler & Rei, 2023. "TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    3. John P. Finnigan & Jenna H. Newman & Yury Patskovsky & Larysa Patskovska & Andrew S. Ishizuka & Geoffrey M. Lynn & Robert A. Seder & Michelle Krogsgaard & Nina Bhardwaj, 2024. "Structural basis for self-discrimination by neoantigen-specific TCRs," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    4. Jens Bauer & Natalie Köhler & Yacine Maringer & Philip Bucher & Tatjana Bilich & Melissa Zwick & Severin Dicks & Annika Nelde & Marissa Dubbelaar & Jonas Scheid & Marcel Wacker & Jonas S. Heitmann & S, 2022. "The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma," Nature Communications, Nature, vol. 13(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:547:y:2017:i:7662:d:10.1038_nature23003. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.